Hal Barron

Chief Scientific Officer & President of Research & Development at GlaxoSmithKline Plc

Hal Barron

Hal Barron

Chief Scientific Officer & President of Research & Development at GlaxoSmithKline Plc

Overview
Career Highlights

TESARO, Inc.

RelSci Relationships

6029

Number of Boards

6

Birthday

1963

Age

58

Relationships
RelSci Relationships are individuals Hal Barron likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at GlaxoSmithKline Plc

Relationship likelihood: Strong

Chief Executive Officer at GRAIL, Inc.

Relationship likelihood: Strong

Co-Founder at Mindstrong Health

Relationship likelihood: Strong

Chief Financial Officer at GlaxoSmithKline Plc

Relationship likelihood: Strong

Senior Vice President & Head of Worldwide Business Development for Pharmaceuticals Research & Development at GlaxoSmithKline Plc

Relationship likelihood: Strong

Head, Functional Genomics at GlaxoSmithKline Plc

Relationship likelihood: Strong

Co-Owner at The Foundation Fighting Blindness, Inc.

Relationship likelihood: Strong

President & Representative Director, GSK-Japan at GlaxoSmithKline Plc

Relationship likelihood: Strong

Co-Founder at GRAIL, Inc.

Relationship likelihood: Strong

President at Stanford University

Relationship likelihood: Strong

Paths to Hal Barron
Potential Connections via
Relationship Science
You
Hal Barron
Chief Scientific Officer & President of Research & Development at GlaxoSmithKline Plc
Education
Bachelor of Science in Physics

The mission of Washington University in St. Louis is the promotion of learning — learning by students and by faculty. Teaching, the transmission of knowledge, is central to our mission, as is research, the creation of new knowledge. Faculty — composed of scholars, scientists, artists and members of the learned professions — serve society by teaching; by adding to the store of human art, creativity, understanding, and wisdom; and by providing direct services, such as health care. The university offers more than 90 programs and almost 1,500 courses leading to bachelor's, master's and doctoral degrees in a broad spectrum of traditional and interdisciplinary fields, with additional opportunities for minor concentrations and individualized programs.

MD

Yale University School of Medicine provides higher education and professional qualifications related to the health industry. It offers the Doctor of Medicine (M.D.) degree and a Master of Medical Science (M.M.Sc.) degree through the Yale Physician Associate Program for prospective physician assistants. Public health degrees are administered through the Yale School of Public Health. It also provides joint degree programs with other disciplines at Yale, including the M.D/Juris Doctor (J.D.) in conjunction with Yale Law School; the M.D./Master of Business Administration (M.B.A.) in conjunction with the Yale School of Management; the M.D./Master of Public Health (M.P.H.) in conjunction with the Yale School of Public Health; science or engineering in conjunction with the Yale Graduate School of Arts and Sciences (M.D./Ph.D.); and the M.D./Master of Divinity (M.Div) in conjunction with Yale Divinity School. Yale University School of Medicine carries out its practical teaching through the Yale-New Haven Hospital. It includes 62 National Academy of Sciences members, 40 Institute of Medicine investigators, and 16 Howard Hughes Medical Institute investigators. It has 718 students and 2,451 academic staff. It was founded in 1810 as The Medical Institution of Yale College, and formally opened its doors in 1813. Yale University School of Medicine is based in New Haven, Connecticut.

Career History
Chief Medical Officer & Executive Vice President, Global Development
1996 - 2013

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer, Kenneth B. Lee and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Chief Medical Officer & Executive Vice President
2010 - 2013

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Director & Senior Vice President-Development
Prior

Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA.

Boards & Committees
Member, Board of Directors
2018 - Current

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Member, Board of Directors
2018 - Current

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Independent Non-Executive Director
2014 - 2018

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

National Trustee
Current

The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hal Barron. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hal Barron's profile does not indicate a business or promotional relationship of any kind between RelSci and Hal Barron.